

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Genitourinary disease				
Incontinence	Transient receptor potential vanilloid 4 (TRPV4; VRL2)	<p>Studies in rodents suggest that antagonizing TRPV4 could help treat overactive bladder. In a mouse model of bladder dysfunction, <i>Trpv4</i> deficiency decreased voiding frequency compared with that of wild-type controls. In mouse and rat models of bladder dysfunction, a selective TRPV4 antagonist decreased voiding frequency compared with vehicle control. Next steps include studying the molecular mechanisms that allow TRPV4 to sense the filling state of the bladder and performing medicinal chemistry optimization of the antagonist.</p> <p>SciBX 3(43); doi:10.1038/scibx.2010.1291 Published online Nov. 4, 2010</p>	Patent application filed by Hydra Biosciences Inc.; available for licensing	<p>Everaerts, W. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Oct. 18, 2010; doi:10.1073/pnas.1005333107 Contact: Christopher M. Fanger, Hydra Biosciences Inc., Cambridge, Mass. e-mail: cfanger@hydrabiosciences.com Contact: Thomas Voets, Catholic University Leuven, Leuven, Belgium e-mail: thomas.voets@med.kleuven.be</p>